BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Sold by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd lessened its holdings in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 919,587 shares of the company’s stock after selling 91,877 shares during the quarter. BeOne Medicines makes up approximately 0.9% of Temasek Holdings Private Ltd’s holdings, making the stock its 21st largest position. Temasek Holdings Private Ltd’s holdings in BeOne Medicines were worth $279,380,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Strategic Global Advisors LLC purchased a new position in shares of BeOne Medicines during the fourth quarter worth about $336,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of BeOne Medicines by 17.5% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 3,270 shares of the company’s stock valued at $993,000 after acquiring an additional 486 shares during the period. Panagora Asset Management Inc. lifted its position in shares of BeOne Medicines by 2,504.0% during the 4th quarter. Panagora Asset Management Inc. now owns 32,941 shares of the company’s stock valued at $10,008,000 after acquiring an additional 31,676 shares during the period. MML Investors Services LLC increased its stake in shares of BeOne Medicines by 9.7% during the 4th quarter. MML Investors Services LLC now owns 5,169 shares of the company’s stock worth $1,570,000 after purchasing an additional 455 shares in the last quarter. Finally, Mariner LLC increased its stake in shares of BeOne Medicines by 3.8% during the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after purchasing an additional 32 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 626 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $261.20, for a total value of $163,511.20. Following the completion of the sale, the chief operating officer owned 1,308,161 shares in the company, valued at approximately $341,691,653.20. This trade represents a 0.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Lai Wang sold 756 shares of BeOne Medicines stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $261.00, for a total transaction of $197,316.00. Following the sale, the insider owned 1,710,085 shares of the company’s stock, valued at approximately $446,332,185. This represents a 0.04% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 14,657 shares of company stock worth $3,959,036 over the last ninety days. Company insiders own 6.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on ONC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Guggenheim upped their target price on shares of BeOne Medicines from $410.00 to $420.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Barclays upped their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $390.00.

BeOne Medicines Stock Up 1.4%

Shares of NASDAQ:ONC opened at $268.20 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. The company has a market cap of $29.43 billion, a PE ratio of 60.00 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $239.25 and a 52 week high of $385.22. The firm has a 50 day simple moving average of $298.56 and a 200 day simple moving average of $314.03.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.